BACKGROUND: Differences in gene or protein expression patterns between breast cancers according to race/ethnicity and cancer subtype. METHODS: Transcriptional profiling was performed using Affymetrix HG-U133A platform in 376 patients and reverse phase protein array analysis (RPPA) was done for 177 proteins in 255 patients from a separate cohort. Unsupervised clustering was conducted, as well as supervised comparison by race and tumor subtype. Standard statistical methods, BRB-Array tools, and Ingenuity Pathways software packages were used to analyze the data. RESULTS: Median age was 50 years in both the cohorts. In the RPPA cohort, 54.5% of the tumors were hormone receptor-positive (HR-positive), 20.7% HER2-positive, and 24.71% triple-negative (TNBC). One hundred and forty-seven (57.6%), 47 (18.43%), and 46 (18.1%) of the patients were White, Hispanic, and Black, respectively. Unsupervised hierarchical clustering of the protein expression data showed no distinct clusters by race (P values were 0.492, 0.489, and 0.494 for the HR-positive, HER2-positive, and TNBC tumors respectively). In the gene expression cohort, 54.2% of the tumors were HR-positive, 16.5% HER2-positive, and 29.3% TNBC. Two hundred and sixteen (57.5%), 111 (29.52%), and 32 (8.52%) patients were White, Hispanic, and Black, respectively. No probe set with a false discovery rate (FDR) of <0.05 showed an association with race by breast cancer subtype; similar results were obtained using pathway and gene set enrichment analysis methods. CONCLUSIONS: We did not detect a significant variation in RNA or protein expression comparing different race/ethnicity groups of women with breast cancer. IMPACT: More research on the complex network of factors that result in outcomes differences among race/ethnicities is needed.
BACKGROUND: Differences in gene or protein expression patterns between breast cancers according to race/ethnicity and cancer subtype. METHODS: Transcriptional profiling was performed using Affymetrix HG-U133A platform in 376 patients and reverse phase protein array analysis (RPPA) was done for 177 proteins in 255 patients from a separate cohort. Unsupervised clustering was conducted, as well as supervised comparison by race and tumor subtype. Standard statistical methods, BRB-Array tools, and Ingenuity Pathways software packages were used to analyze the data. RESULTS: Median age was 50 years in both the cohorts. In the RPPA cohort, 54.5% of the tumors were hormone receptor-positive (HR-positive), 20.7% HER2-positive, and 24.71% triple-negative (TNBC). One hundred and forty-seven (57.6%), 47 (18.43%), and 46 (18.1%) of the patients were White, Hispanic, and Black, respectively. Unsupervised hierarchical clustering of the protein expression data showed no distinct clusters by race (P values were 0.492, 0.489, and 0.494 for the HR-positive, HER2-positive, and TNBC tumors respectively). In the gene expression cohort, 54.2% of the tumors were HR-positive, 16.5% HER2-positive, and 29.3% TNBC. Two hundred and sixteen (57.5%), 111 (29.52%), and 32 (8.52%) patients were White, Hispanic, and Black, respectively. No probe set with a false discovery rate (FDR) of <0.05 showed an association with race by breast cancer subtype; similar results were obtained using pathway and gene set enrichment analysis methods. CONCLUSIONS: We did not detect a significant variation in RNA or protein expression comparing different race/ethnicity groups of women with breast cancer. IMPACT: More research on the complex network of factors that result in outcomes differences among race/ethnicities is needed.
Authors: D Olga McDaniel; Tonya Thurber; Angela Lewis-Traylor; Crystal Berry; William Henry Barber; Xinchun Zhou; Steven Bigler; Ralph Vance Journal: J Investig Med Date: 2011-10 Impact factor: 2.895
Authors: Olufunmilayo I Olopade; James D Fackenthal; Georgia Dunston; Michael A Tainsky; Francis Collins; Carolyn Whitfield-Broome Journal: Cancer Date: 2003-01-01 Impact factor: 6.860
Authors: Jessica M Grunda; Adam D Steg; Qinghua He; Mark R Steciuk; Suzanne Byan-Parker; Martin R Johnson; William E Grizzle Journal: BMC Res Notes Date: 2012-05-22
Authors: Ana M Gonzalez-Angulo; Bryan T Hennessy; Funda Meric-Bernstam; Aysegul Sahin; Wenbin Liu; Zhenlin Ju; Mark S Carey; Simen Myhre; Corey Speers; Lei Deng; Russell Broaddus; Ana Lluch; Sam Aparicio; Powel Brown; Lajos Pusztai; W Fraser Symmans; Jan Alsner; Jens Overgaard; Anne-Lise Borresen-Dale; Gabriel N Hortobagyi; Kevin R Coombes; Gordon B Mills Journal: Clin Proteomics Date: 2011-07-08 Impact factor: 3.988
Authors: Dezheng Huo; Hai Hu; Suhn K Rhie; Eric R Gamazon; Andrew D Cherniack; Jianfang Liu; Toshio F Yoshimatsu; Jason J Pitt; Katherine A Hoadley; Melissa Troester; Yuanbin Ru; Tara Lichtenberg; Lori A Sturtz; Carl S Shelley; Christopher C Benz; Gordon B Mills; Peter W Laird; Craig D Shriver; Charles M Perou; Olufunmilayo I Olopade Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Brittany D Jenkins; Rachel N Martini; Rupali Hire; Andrea Brown; Briana Bennett; I'nasia Brown; Elizabeth W Howerth; Mary Egan; Jamie Hodgson; Clayton Yates; Rick Kittles; Dhananjay Chitale; Haythem Ali; David Nathanson; Petros Nikolinakos; Lisa Newman; Michele Monteil; Melissa B Davis Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-04 Impact factor: 4.090
Authors: Silvia J Serrano-Gómez; María Carolina Sanabria-Salas; Jone Garay; Melody C Baddoo; Gustavo Hernández-Suarez; Juan Carlos Mejía; Oscar García; Lucio Miele; Laura Fejerman; Jovanny Zabaleta Journal: PLoS One Date: 2017-08-23 Impact factor: 3.240
Authors: Sara Bravaccini; Sara Ravaioli; Dino Amadori; Emanuela Scarpi; Maurizio Puccetti; Andrea Rocca; Maria Maddalena Tumedei; Nestory Masalu; Jackson Kahima; Akwilina Pangan; Lucas Faustine; Alberto Farolfi; Roberta Maltoni; Massimiliano Bonafè; Patrizia Serra; Giuseppe Bronte Journal: Front Endocrinol (Lausanne) Date: 2018-03-29 Impact factor: 5.555